ArticleRadiologie (Heidelberg, Germany)2025
[Lymphatic malformations in childhood and adolescence].
Article in Radiologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oxandrolone for burn patients: a systematic review and updated meta-analysis of randomized controlled trials from 2005 to 2025.World journal of emergency surgery : WJES · 2025Pooled it
- A single-center retrospective study of a decade-long experience in managing pediatric lymphatic malformation.BMC pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical issueLymphatic malformations (LM) are congenital abnormalities of the lymphatic system and occur with an incidence of 1:6000-1:16,000 live births. Simple LMs manifest as soft-elastic space-occupying lesions, whereas complex LMs affect several organ systems and can lead to chylous effusions due to lymph leakage. In addition, LM can occur together with other vascular malformations or as part of overgrowth syndromes. Primary lymphedema is a special subgroup of LMs, which can first be clinically manifested in advanced age. DIAGNOSTICS: Imaging procedures are of great importance in the diagnostics of LM, in particular magnetic resonance imaging (MRI) and MR lymphangiography. Additionally, genetic testing should be carried out to detect possible comorbidities at an early stage and to enable targeted treatment. TREATMENT STRATEGIES: The decision for treatment depends on the underlying LM as well as the extent and localization. Medicinal treatment is possible with the mTOR inhibitor sirolimus and with propranolol via the vascular endothelial growth factor (VEGF)-Ras-MAPK pathway, also as a combined treatment, Depending on the results of genetic analyses, targeted treatment with alpelisib/trametinib is also an option. Moreover, surgical and radiological interventional approaches can be used, depending on the underlying findings. PRACTICAL RECOMMENDATIONS: Patients with LM should be referred to an expert center to enable an early diagnosis and treatment in an interdisciplinary team. Together with the clinical and genetic findings MRI and MR lymphangiography enable the evaluation of interventional and surgical treatment options.
Indexed as
Identifiers
40261362What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.